Cellebrite DI (NASDAQ:CLBT) Price Target Raised to $17.00 at Bank of America

Cellebrite DI (NASDAQ:CLBTFree Report) had its price objective lifted by Bank of America from $13.00 to $17.00 in a research note issued to investors on Friday, Benzinga reports. They currently have a buy rating on the stock.

CLBT has been the subject of a number of other reports. JPMorgan Chase & Co. upped their target price on Cellebrite DI from $14.00 to $15.00 and gave the company an overweight rating in a research note on Wednesday, August 14th. Craig Hallum boosted their price target on shares of Cellebrite DI from $16.00 to $20.00 and gave the company a buy rating in a report on Friday. Needham & Company LLC lifted their target price on shares of Cellebrite DI from $14.00 to $17.00 and gave the company a buy rating in a research report on Friday. Finally, Lake Street Capital upped their target price on shares of Cellebrite DI from $13.50 to $17.00 and gave the company a buy rating in a research note on Friday. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Cellebrite DI has an average rating of Buy and a consensus target price of $17.33.

Get Our Latest Research Report on CLBT

Cellebrite DI Price Performance

NASDAQ CLBT opened at $16.37 on Friday. The company’s fifty day moving average is $12.75 and its two-hundred day moving average is $11.63. Cellebrite DI has a 52-week low of $6.36 and a 52-week high of $16.89. The firm has a market capitalization of $3.37 billion, a price-to-earnings ratio of -28.22, a P/E/G ratio of 1.90 and a beta of 1.50.

Cellebrite DI (NASDAQ:CLBTGet Free Report) last released its earnings results on Thursday, August 15th. The company reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of $0.08 by $0.02. The business had revenue of $95.70 million for the quarter, compared to the consensus estimate of $91.94 million. Cellebrite DI had a positive return on equity of 417.94% and a negative net margin of 32.57%. The firm’s revenue for the quarter was up 24.8% compared to the same quarter last year. During the same period last year, the business earned $0.05 earnings per share. As a group, sell-side analysts expect that Cellebrite DI will post 0.34 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Cellebrite DI

Institutional investors have recently added to or reduced their stakes in the company. Point72 Asia Singapore Pte. Ltd. grew its stake in Cellebrite DI by 59.6% during the second quarter. Point72 Asia Singapore Pte. Ltd. now owns 2,724 shares of the company’s stock worth $33,000 after buying an additional 1,017 shares during the last quarter. Parallel Advisors LLC grew its position in Cellebrite DI by 75.0% during the 4th quarter. Parallel Advisors LLC now owns 3,500 shares of the company’s stock worth $30,000 after acquiring an additional 1,500 shares during the last quarter. Quarry LP acquired a new stake in Cellebrite DI during the 4th quarter valued at $36,000. Public Employees Retirement Association of Colorado acquired a new stake in Cellebrite DI during the 2nd quarter valued at $71,000. Finally, nVerses Capital LLC bought a new position in Cellebrite DI in the 2nd quarter valued at $103,000. 45.88% of the stock is owned by institutional investors.

Cellebrite DI Company Profile

(Get Free Report)

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.

See Also

Analyst Recommendations for Cellebrite DI (NASDAQ:CLBT)

Receive News & Ratings for Cellebrite DI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellebrite DI and related companies with MarketBeat.com's FREE daily email newsletter.